Key result
Aortic root and ascending aorta replacement using the BioValsalva preassembled stentless valved-conduit resulted in 0% perioperative mortality, myocardial infarction, cardiac failure, or stroke.
Why the study?
Is a preassembled stentless valved-conduit safe and effective for the replacement of the ascending aorta and aortic root?
Observational (n=17)
Is a preassembled stentless valved-conduit safe and effective for the replacement of the ascending aorta and aortic root?
A novel preassembled stentless valved-conduit demonstrates excellent early hemodynamic performance and safety for aortic root and ascending aorta replacement.
Here we report the early clinical results of a new preassembled stentless valved-conduit incorporating artificial sinuses of Valsalva (BioValsalva). This new composite conduit incorporates a stentless porcine aortic valve (Elan, Vascutek Terumo, UK) suspended within a triple-layered vascular conduit (Triplex, Vascutek Terumo, UK) constructed with sinuses of Valsalva. Between December 2006 and January 2008, 17 patients with the mean age of 65 years underwent aortic valve, root and ascending aorta replacement with the BioValsalva valved-conduit. There was no perioperative mortality. There were no myocardial infarctions, cardiac failure or cerebrovascular events. Mean cardiopulmonary bypass time was 156+/-56 min and ischemic time was 112+/-33 min. Eight patients required deep hypothermic circulatory arrest for additional distal ascending aorta replacement. Mean mediastinal drainage was 499+/-262 ml. Postoperative transthoracic echocardiography and CT-scans of the aorta in all patients before discharge demonstrated well-functioning prosthetic aortic valves with small residual mean gradients, no regurgitation, and the presence of sinuses of Valsalva. In conclusion, the novel prefabricated, composite stentless valved-conduit BioValsalva possesses excellent hemodynamic performance and can be implanted with low morbidity. In addition, the conduit material has good hemostatic properties which reduced bleeding, and is easy to implant with a variety of surgical techniques.
No takes yet. Share an insight, caveat, or question.
Bochenek−Klimczyk et al. (2008) conducted an observational in Aortic root and ascending aorta disease requiring replacement (n=17). BioValsalva preassembled stentless valved-conduit was evaluated on Perioperative mortality. Aortic root and ascending aorta replacement using the BioValsalva preassembled stentless valved-conduit resulted in 0% perioperative mortality, myocardial infarction, cardiac failure, or stroke.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: